To achieve a consistent contrast enhancement in cardiac CT angiography (CTA), contrast-medium dose should be adjusted with the body weight or the BSA (which accounts for both the body weight and height factors) to provide adjustment of iodine dose over a wide range of body sizes.

Gadoxetate disodium-enhanced MR imaging is more reliable for staging hepatic fibrosis than are diffusion-weighted MR imaging, hematologic, and clinical parameters.

Advances in image quality over the past few years, mainly due to refinements in hardware and coil systems, have made diffusion-weighted ( DW diffusion weighted ) magnetic resonance (MR) imaging a promising technique for the detection and characterization of pancreatic conditions. DW diffusion weighted MR imaging can be routinely implemented in clinical protocols, as it can be performed relatively quickly, does not require administration of gadolinium-based contrast agents, and enables qualitative and quantitative assessment of tissue diffusivity (diffusion coefficients). In this review, acquisition parameters, postprocessing, and quantification methods applied to pancreatic DW diffusion weighted MR imaging will be discussed. The current common clinical uses of DW diffusion weighted MR imaging (ie, pancreatic lesion detection and characterization) and the less-common applications of DW diffusion weighted MR imaging used for the diagnosis of pancreatic parenchymal diseases will be reviewed. Also, the limitations of the technique, mainly image quality and reproducibility of diffusion parameters, as well as future directions for pancreatic DW diffusion weighted MR imaging will be discussed. The utility of apparent diffusion coefficient ( ADC apparent diffusion coefficient ) measurement for the characterization of pancreatic lesions is now well accepted but there are a number of limitations. Future well-designed, multicenter studies are needed to better determine the most appropriate use of ADC apparent diffusion coefficient in the area of pancreatic disease.

MRI allows the identification of a wide spectrum of appearances of untreated liver metastases. The extent and pattern of enhancement of various histologic types of tumor are depicted on MRI.

Purpose: To assess MR imaging findings and clinical manifestations of diffuse-type hepatocellular carcinoma (HCC). Materials and Methods:We retrospectively reviewed our experience with diffuse HCC from November 1994 to October 2001. MR imaging findings and clinical features were assessed.Results: Twenty-two consecutive patients with diffuse-type HCC (19 men and three women, age range 16 -80 years [mean, 52 years]) were identified in a review of liver MR studies. This represented 13% of all patients with HCC imaged during this time period. Diffuse HCC showed a permeative, infiltrative pattern with ill-defined borders and no evidence of convex margination in all cases. At least 50% of the liver volume was involved with tumor. Diffuse-type HCC showed hypointensity in 15 patients, mixed intensity in three, and isointensity in four on T1-weighted images; heterogeneous hyperintensity in 16 patients; and homogeneous hyperintensity in six on T2-weighted MR images. Diffuse-type HCC showed patchy enhancement in 12 patients, miliary enhancement in nine, and minimal enhancement in one on postcontrast early-phase images, and showed heterogeneous washout in all patients on postcontrast late-phase images. Proximal portal venous tumor thrombosis was seen in all patients. Serum ␣-fetoprotein (AFP) value was elevated (Ͼ10 ng/mL) in 14 of 18 patients, and 13 showed a value greater than 500 ng/mL. The four patients who did not have elevated AFP had tumors which were indistinguishable from those in patients with elevated AFP; they also did not have a distinctive clinical history.Conclusion: Diffuse-type HCC was typically seen as an extensive, heterogeneous permeative hepatic tumor, with portal venous tumor thrombosis on MR images in all cases. Early enhancement, observed as patchy in 12 and miliary in nine of 22 patients, was a distinctive imaging feature. Elevated serum AFP value was a common finding; however, 22% had normal values.